Morningside

Xealth Inc. is a digital health company that has developed a comprehensive platform enabling clinicians to integrate, prescribe, and monitor various digital health tools and programs directly from electronic health record (EHR) workflows. Founded in 2016 and based in Seattle, Washington, Xealth's platform allows care teams to efficiently order digital health solutions for patients, facilitating seamless communication through email or patient portals. The platform also provides functionality for monitoring patient engagement and analyzing the impact of these tools on patient outcomes. Additionally, Xealth supports non-clinical services, such as ride-sharing and food delivery, enhancing the overall patient experience and promoting greater utilization of digital health resources.

Accro Bioscience is a biopharmaceutical company that specializes in the development of innovative small molecule drugs aimed at treating inflammatory and autoimmune diseases, as well as cancer. The company conducts research on the molecular mechanisms underlying regulated cell death processes, including necroptosis, pyroptosis, and ferroptosis. By understanding these mechanisms, Accro Bioscience aims to enhance current therapeutic approaches and address specific pathologies associated with various human diseases.

League is a platform technology company focused on enhancing healthcare consumer experiences through its digital health platform. This platform is designed to deliver personalized health experiences, facilitating a digital transformation in the healthcare sector. By providing a robust infrastructure, League enables healthcare providers, partners, and employers to manage costs, increase utilization, and improve care for their populations. The company's approach aims to meet consumers in various settings, driving measurable outcomes in health engagement and overall wellness.

SimpliFed is a telehealth company founded in 2020 that focuses on providing virtual breastfeeding support to new and expectant parents. It addresses the challenges faced by these individuals, such as sleep deprivation and concerns about infant nutrition. SimpliFed offers a maternal care platform that delivers virtual-first care throughout the peri and postnatal periods. The company specializes in lactation and baby feeding support, as well as monitoring high-risk conditions like hypertension and gestational diabetes. By engaging with patients early, SimpliFed’s care navigators facilitate a comprehensive maternal care experience, allowing parents to receive timely answers to their questions about infant feeding through secure online and video connections.

AdvanCell is a clinical-stage radiopharmaceutical company focused on developing innovative cancer therapeutics. The company specializes in alpha-emitting isotopes that are linked to molecules designed to deliver targeted cytotoxic radiation directly to tumors. This approach allows for radiotherapy at the molecular level, addressing significant challenges in targeted alpha therapy, particularly in ensuring a reliable and scalable supply. AdvanCell aims to provide safe and effective treatment options for various forms of cancer, with the goal of establishing its therapies as a standard of care in oncology.

Geneoscopy, LLC is a diagnostics company based in Saint Louis, Missouri, that specializes in non-invasive colorectal cancer screening and gastrointestinal disease management. Founded in 2015, Geneoscopy has developed a platform technology that utilizes stool-derived eukaryotic RNA (seRNA) to create a multi-target RNA biomarker panel. This innovative approach allows for the identification of colorectal cancer by capturing the downstream effects of cancer-causing DNA mutations. The company's diagnostic test aims to improve compliance with colorectal cancer screening, facilitate early-stage detection of neoplasms, and ultimately reduce morbidity and mortality associated with the disease. Additionally, Geneoscopy is exploring other applications of its technology for various gastrointestinal conditions, aiming to provide reliable alternatives to traditional invasive procedures like colonoscopy.

Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, specializing in the development of innovative therapies for advanced liver diseases and cancers associated with Claudin-1 (CLDN1) expression. Founded in 2019, Alentis focuses on addressing conditions such as liver fibrosis, cirrhosis, and liver cancer through the use of anti-CLDN1 antibody-drug conjugates and other targeted treatments. The company's unique approach combines clinically relevant read-outs with advanced techniques like single-cell RNA sequencing of patient liver tissues, aiming to reverse disease progression and improve patient outcomes. Alentis Therapeutics is recognized for its pioneering role in exploring anti-CLDN1 therapeutics, contributing to advancements in the treatment of fibrotic diseases and CLDN1-positive tumors.

CairnSurgical is a company focused on creating innovative, patient-specific tools designed to enhance the precision and accuracy of surgical interventions for cancer patients. By utilizing patient imaging data alongside advanced 3D printing technologies, CairnSurgical develops image guidance devices that assist healthcare professionals in achieving improved surgical outcomes. The company's commitment to personalized medical solutions aims to transform the surgical experience for patients, ensuring that interventions are tailored to their specific anatomical needs.

Kappa Pay is a fintech platform that utilizes blockchain technology to streamline payment processes for both local and cross-border transactions. The company aims to provide an affordable and reliable solution for individuals and merchants, facilitating seamless payments that resemble the simplicity of sending a message. By focusing on removing friction and barriers in financial transactions, Kappa enables users to send and receive money globally with higher transaction limits, enhancing the overall efficiency of the payment experience.

ENYO Pharma SA is a clinical-stage biopharmaceutical company based in Lyon, France, founded in 2014 by scientists from the Infectiology Research Center. The company focuses on drug discovery and development for the treatment of acute and chronic viral infections, utilizing a unique platform to identify intracellular therapeutic targets and molecules. ENYO Pharma is developing a pipeline of drug candidates addressing various indications, including hepatitis B virus, nonalcoholic steatohepatitis, and oncology. Its lead compound, EYP001, is designed to modulate specific nuclear receptors, aiming to reduce viral reservoirs and inhibit harmful viral protein expression. The company is also advancing EYP002 through preclinical studies. ENYO Pharma collaborates closely with established research institutions and aims to conduct its molecules into Phase II clinical trials, striving to become a global leader in antiviral therapeutics.

Suvera Ltd, incorporated in 2019 and based in London, United Kingdom, develops a virtual care follow-up application aimed at enhancing primary care for patients with long-term conditions. The company's platform enables general practices to manage patients virtually, focusing on conditions such as hypertension, diabetes, asthma, chronic obstructive pulmonary disease, depression, and anxiety. By facilitating remote follow-up care, Suvera aims to improve patient outcomes, reduce hospital admissions, and decrease the frequency of doctor appointments, ultimately allowing patients to spend more time in good health and achieve their personal health milestones.

Pelicargo operates an air cargo marketplace platform designed to simplify the process of air freight shopping for freight forwarders. By leveraging a large network of airline partners, the company automatically matches cargo with available flight options, allowing transporters to access and book optimal air freight rates with ease. Pelicargo streamlines the procurement process by providing accurate quotations and facilitating quote requests from airlines, thereby reducing the repetitive tasks typically associated with air freight logistics. This innovative approach enhances efficiency and accessibility in the air cargo sector.

FireCyte Therapeutics is a biotechnology company dedicated to developing innovative treatments for progressive neurodegenerative eye diseases by targeting microglia and neuroinflammation. The company focuses on novel protein constructs designed to engage both microglia and neurons, aiming to mitigate harmful neuroinflammatory processes while promoting neuroprotection. Their therapeutic strategies are specifically tailored to address critical unmet needs in conditions such as glaucoma and age-related macular degeneration. Through its research and development efforts, FireCyte Therapeutics seeks to advance the understanding and treatment of neurodegenerative diseases affecting vision, ultimately improving patient outcomes.

Jitjatjo is a workforce management platform and talent marketplace designed to address staffing challenges primarily in the Leisure & Hospitality and Retail sectors. The company offers an on-demand staffing solution through its contingent labor marketplace, Ondemand, and provides enterprise clients with a software-as-a-service platform, Network, to help transform their labor models. By leveraging artificial intelligence and empathic intelligence, Jitjatjo specializes in payroll and hiring processes, allowing businesses to meet their personalized and on-demand staffing requirements. The company's vision is to revolutionize work dynamics to enhance productivity and support individual lifestyle choices, while its mission focuses on creating opportunities for the next-generation workforce.

Angitia Biopharmaceuticals is a global biotechnology company dedicated to the discovery and development of innovative therapeutics targeting serious musculoskeletal diseases. The company specializes in researching and developing breakthrough therapies for conditions affecting bones, muscles, and joints. By focusing on creating novel drugs, Angitia aims to provide effective treatments that enhance patient recovery from severe musculoskeletal ailments.

Epigenic Therapeutics is a biotechnology company focused on developing gene editing therapies that leverage gene-silencing technology to address a range of diseases. The firm specializes in epigenome editing, aiming to regulate various conditions, including those related to ophthalmology, neurodegeneration, metabolism, and rare diseases. By creating innovative treatments, Epigenic Therapeutics seeks to offer effective solutions for patients suffering from chronic and severe health issues.

GaeaStar is a manufacturer focused on creating environmentally friendly products aimed at reducing waste and pollution. The company has developed patented technology to produce a new category of uniquely thin clay cups made from locally sourced, natural materials. With an estimated 500 billion single-use cups used annually and less than 1% recycled, GaeaStar addresses the urgent need for sustainable alternatives, particularly as industries face pressure to adopt circular solutions by 2030. By utilizing geo-neutral materials and efficient additive manufacturing techniques, GaeaStar's products are designed to be sustainable and produce zero waste, thereby promoting conscious consumption while enhancing performance and cost-effectiveness for businesses and consumers alike.

Cognito Therapeutics, established in 2016 and headquartered in Newton Centre, Massachusetts, with additional locations in San Francisco and Boston, is a clinical-stage neurotechnology company. It specializes in developing non-invasive, device-based therapies to treat neurodegenerative diseases, with a primary focus on Alzheimer's disease. The company's innovative approach involves using induced brain wave oscillations to reactivate the immune system in the brain, aiming to reduce typical disease hallmarks such as amyloid plaques and tau tangles. Co-founded by MIT professors Li-Huei Tsai and Ed Boyden, Cognito's lead therapy is currently in a pivotal study for Alzheimer's, and has been recognized as a Breakthrough Device by the FDA.

PhagePharm is a company focused on the industrialization of bacteriophages, specifically developing antibiotics and phage products for the animal breeding industry. The organization creates a range of effective disease immunization solutions aimed at enhancing the health of animals and supporting the growth of the animal breeding and agricultural sectors. By providing innovative health products, PhagePharm aims to improve overall animal health and productivity within these industries.

LumiraDx Ltd, incorporated in 2016 and based in London, United Kingdom, is a next-generation point-of-care diagnostics company. It specializes in manufacturing an innovative diagnostic platform that provides a wide range of tests with lab-comparable performance. LumiraDx aims to transform healthcare by offering solutions that facilitate integrated, patient-centered care, enhancing safety, efficiency, and health outcomes. The company's diagnostic system includes a portable instrument, low-cost test strips, and seamless digital connectivity, making diagnostic-led care simpler and more accessible. LumiraDx operates in multiple countries, including the United States, Italy, Germany, and Sweden, with a significant portion of its revenue generated from the U.S. market.

Evonetix Ltd is a biotechnology company based in Little Chesterford, United Kingdom, founded in 2015. The company specializes in the development of a novel technology that allows for the parallel synthesis of DNA on silicon arrays, thereby advancing the field of synthetic biology. Evonetix aims to enhance DNA synthesis accuracy and scalability, making it accessible to researchers and transforming how DNA is produced and utilized for gene synthesis. With a highly experienced engineering team that combines expertise from various scientific and engineering disciplines, Evonetix is positioned to significantly impact the capabilities of synthetic biology by enabling applications that were previously unfeasible.

Zhide New Energy is a developer of approaches to synthetize new silicon anode materials. They focuses on silicon technology that can be applied to produce new materials. They also produce battery with high energy density and low cost. They manufactures battery for 3C and EV. They provide batteries for fields, such as electric vehicles, consumer electronics, house power storage, and wearable devices.

Mevox translates molecular characterization, design, and engineering into conformationally precise and optimized protein antigens.

WiseConn is a technology company focused on addressing resource management challenges, particularly in the areas of water usage in agriculture, mining, and hydrology. The company has developed a comprehensive platform that integrates wireless hardware and accessible software to facilitate real-time monitoring and control of water and other fluids. This platform allows users to manage various aspects of agricultural operations, including fertigation, climate conditions, soil moisture, and plant health. By enabling field managers to wirelessly monitor and automate irrigation systems, WiseConn aims to enhance efficiency, reduce water consumption, and improve overall productivity in resource-sensitive environments.

Resilience Lab is a company focused on enhancing the delivery of mental health care through innovative clinical services and therapy centers. It aims to expand access to mental health resources by offering a range of services, including individual, couple, and family therapy, as well as parenting support, nutrition therapy, and weight management. By providing personalized and high-quality care, Resilience Lab seeks to empower individuals and families to achieve sustainable mental and physical well-being. The company emphasizes a collaborative approach among clinicians to ensure that clients receive comprehensive support tailored to their unique needs.

CollegeVine is a technology company based in Cambridge, Massachusetts, founded in 2013. Initially operating as Admissions Hero LLC until August 2016, the company provides mentorship, college application guidance, essay assistance, tutoring, and test preparation services through its platform. In recent years, CollegeVine has expanded into developing Artificial Intelligence (AI) agents to automate administrative tasks in higher education institutions, aiming to save time and money while improving student experiences. Over 100 universities currently utilize CollegeVine's AI Agents to enhance operational efficiency.

Valitor, Inc. is a biotechnology company based in Berkeley, California, founded in 2010. The company specializes in the development of advanced, protein-based drugs and has established innovative methods for modifying therapeutic proteins. This technology enables enhanced control over pharmacokinetics, target specificity, and bioactivity, thus improving the pharmacological properties of existing and emerging protein drugs. Valitor's research and development efforts are focused on three key areas: dermatology, ophthalmology, and orthopedics, where they are advancing novel drug products designed to address unmet medical needs in these fields.

Kezar Life Sciences, Inc. is a clinical-stage biotechnology company based in South San Francisco, California, focused on the discovery and development of small molecule therapeutics aimed at addressing unmet medical needs in autoimmunity and cancer. The company's lead product candidate, KZR-616, is a selective immunoproteasome inhibitor currently undergoing Phase 2 clinical trials for five autoimmune conditions, including lupus nephritis and autoimmune hemolytic anemia, as well as Phase 1b/2 trials in systemic lupus erythematosus. In addition to KZR-616, Kezar is developing KZR-261, which targets oncology and autoimmune indications. Founded in 2015, the company leverages innovative research in protein homeostasis and has established a pipeline of potential therapies to advance treatment options for patients.

Kappa Pay is a fintech platform that utilizes blockchain technology to streamline payment processes for both local and cross-border transactions. The company aims to provide an affordable and reliable solution for individuals and merchants, facilitating seamless payments that resemble the simplicity of sending a message. By focusing on removing friction and barriers in financial transactions, Kappa enables users to send and receive money globally with higher transaction limits, enhancing the overall efficiency of the payment experience.

AdvanCell is a clinical-stage radiopharmaceutical company focused on developing innovative cancer therapeutics. The company specializes in alpha-emitting isotopes that are linked to molecules designed to deliver targeted cytotoxic radiation directly to tumors. This approach allows for radiotherapy at the molecular level, addressing significant challenges in targeted alpha therapy, particularly in ensuring a reliable and scalable supply. AdvanCell aims to provide safe and effective treatment options for various forms of cancer, with the goal of establishing its therapies as a standard of care in oncology.

GreenLight Biosciences, Inc. is a biotechnology company headquartered in Medford, Massachusetts, with an additional location in North Carolina. Founded in 2008, the company specializes in developing RNA-based solutions for agricultural and pharmaceutical purposes. It offers a proprietary technology platform that enables the efficient and cost-effective production of high-quality RNA, facilitating advancements in vaccine development, pandemic response, crop management, and the protection of pollinators. GreenLight develops mRNA-based vaccine candidates, including those aimed at preventing SARS-CoV-2 infections, and engages in collaborative efforts with industry leaders to further enhance its offerings. Through its innovative approach, GreenLight aims to contribute significantly to sustainable global development and food security.

Epigenic Therapeutics is a biotechnology company focused on developing gene editing therapies that leverage gene-silencing technology to address a range of diseases. The firm specializes in epigenome editing, aiming to regulate various conditions, including those related to ophthalmology, neurodegeneration, metabolism, and rare diseases. By creating innovative treatments, Epigenic Therapeutics seeks to offer effective solutions for patients suffering from chronic and severe health issues.

Bevi is a manufacturer of innovative bottle-less water dispensers designed for offices and commercial spaces. The company's smart dispensers provide customizable flavored drinks made from filtered tap water and natural ingredients, allowing users to create beverages tailored to their preferences. Bevi's products also offer features such as nutrition information and environmental impact tracking, promoting healthier and more eco-friendly hydration options for employees. By eliminating the need for bottled beverages, Bevi aims to reduce waste associated with production, shipping, and disposal, envisioning a future where its platform transforms beverage delivery through the use of municipal water supplies.

Airspace Link, Inc. is a company that specializes in developing software solutions for the management of local government airspace for drones. Founded in 2018 and based in Michigan, the company offers a range of products designed to facilitate safe and efficient drone operations. Its key offerings include AirRegistry, which automates approvals for drone package deliveries; AirInspect, a set of tools for inspecting and approving drone delivery sites; AirHub, which generates necessary infrastructure for drone delivery networks, such as flight corridors and no-fly zones; and AirLink, enabling state and local governments to collaborate with drone delivery services. By digitizing local airspace, Airspace Link supports urban air mobility and promotes the responsible growth of drone operations for businesses, citizens, and government entities.

Eko Health is a leading digital health company advancing how healthcare professionals detect and monitor heart and lung disease with its portfolio of digital stethoscopes, patient and provider software, and AI-powered analysis. Its FDA-cleared platform is used by hundreds of thousands of healthcare professionals worldwide, allowing them to detect earlier and with higher accuracy, diagnose with more confidence, manage treatment effectively, and ultimately give their patients the best care possible. Eko Health is headquartered in Emeryville, California, with over $125 million in funding from Highland Capital Partners, Questa Capital, Artis Ventures, DigiTx Partners, NTTVC, Morningside Technology Ventures Limited, Mayo Clinic, Sutter Health, and others. For more information visit www.ekohealth.com.

Adiso Therapeutics is a biopharmaceutical company focused on developing innovative treatments for inflammatory diseases. Its pipeline comprises small molecule drugs and live biotherapeutic products, each with unique mechanisms of action aimed at addressing current treatment limitations and safety concerns. The company's mission is to improve the health of patients suffering from debilitating inflammatory conditions by advancing novel therapies that could potentially cure these diseases.

Cydar Medical is an AI technology company that focuses on enhancing patient care through advanced computer vision software. The company's platform delivers real-time automated 3D overlays during X-ray guided procedures, allowing clinicians to focus more on their patients rather than managing display adjustments. By leveraging cloud supercomputing, Cydar ensures high-performance overlay updates that support clinical decision-making. Additionally, the company offers a cloud-based clinical platform accompanied by a team of specialists who help hospitals fully utilize clinical applications and data insights, thereby advancing the quality of care provided to patients.

Curve Health, Inc. is an innovative online platform focused on enhancing senior care by integrating telemedicine, health information exchange, smart billing, and predictive analytics. Established in 2020 and headquartered in New York, the company aims to improve healthcare delivery for seniors by facilitating remote patient care across various settings, including skilled nursing facilities, homes, and ambulances. Curve Health's platform has successfully reduced patient transfers from skilled nursing facilities to emergency departments by over 50%. It streamlines care coordination between hospital systems and post-acute facilities, automates billing processes, and enhances the tracking of patient diagnoses and outcomes. By bridging existing gaps in healthcare delivery, Curve Health seeks to optimize resource allocation, minimize readmissions, and ensure a seamless experience for patients, ultimately leading to improved care quality and financial returns for healthcare providers.

GreenLight Biosciences, Inc. is a biotechnology company headquartered in Medford, Massachusetts, with an additional location in North Carolina. Founded in 2008, the company specializes in developing RNA-based solutions for agricultural and pharmaceutical purposes. It offers a proprietary technology platform that enables the efficient and cost-effective production of high-quality RNA, facilitating advancements in vaccine development, pandemic response, crop management, and the protection of pollinators. GreenLight develops mRNA-based vaccine candidates, including those aimed at preventing SARS-CoV-2 infections, and engages in collaborative efforts with industry leaders to further enhance its offerings. Through its innovative approach, GreenLight aims to contribute significantly to sustainable global development and food security.

Casana, officially known as Heart Health Intelligence Inc., is a healthcare technology company based in Rochester, New York, founded in 2018. It specializes in developing innovative solutions for heart health monitoring, primarily through its flagship product, the Heart Seat. This smart toilet seat is designed to facilitate effortless and continuous in-home health monitoring by capturing essential clinical measurements such as heart rate, blood pressure, cardiac output, ECG, and blood oxygenation. The Heart Seat integrates advanced sensors, including a single-lead ECG, embedded photoplethysmogram LEDs, and sensitive weight sensors, to monitor cardiac activity. By offering a cloud-connected platform, Casana enables healthcare practitioners to track patients' cardiac health beyond traditional clinical settings, thereby enhancing the management of chronic conditions and improving patient outcomes through reliable and consistent vital signs analysis.

Big Health is a digital therapeutics company headquartered in London, United Kingdom, that specializes in developing and marketing innovative behavioral health programs. The company's flagship product, Sleepio, is a digital sleep improvement program that employs Cognitive Behavioral Therapy techniques to address and personalize sleep disorders. By offering a fully automated healthcare portal, Big Health delivers highly personalized digital therapeutics and behavioral programs aimed at tackling various mental health issues. Their approach combines medical consultation with user-friendly technology, enabling individuals to effectively manage and overcome sleep-related disorders in an efficient manner.

Virtue Diagnostics (Suzhou) Co., Ltd. is an in vitro diagnostic (IVD) company based in Suzhou, China, with a research and development office in Singapore. Founded in 2019, the company specializes in developing advanced diagnostic platforms for the detection of infectious diseases, cancer, and chronic diseases. Its technology offerings include clinical mass spectrometry, multiplex immunohistochemistry for pathology-based cancer detection, and a molecular and immunoassay platform. Virtue Diagnostics aims to enhance diagnostic capabilities and improve patient outcomes through its innovative solutions.

Almond Fintech, headquartered in Boston and Singapore, is a blockchain-based infrastructure facilitating cross-border funds transfers for financial institutions worldwide. The company connects hundreds of institutions, allowing millions of users to send money internationally through their existing financial services. Almond's platform is designed for speed, security, and accessibility, and includes a suite of APIs that support peer-to-peer transfers and digital currency-based settlements. Additionally, it offers interoperability between various mobile wallets and services, enabling both individuals and businesses to efficiently conduct remittances and payments across different providers and borders.

Ieso Digital Health Ltd. is a United Kingdom-based company specializing in online evidence-based mental health therapy. Founded in 2000 and formerly known as PsychologyOnline.co.uk Limited, Ieso provides a platform for one-to-one therapy sessions, allowing patients to engage with accredited therapists in a virtual environment tailored to their schedules. The company addresses a variety of mental health conditions, including anxiety, depression, eating disorders, and relationship issues, as well as chronic physical health problems and cognitive impairments. Utilizing cognitive behavioral therapy (CBT), Ieso employs proprietary technology enhanced by natural language processing and artificial intelligence to facilitate real-time monitoring and improve therapeutic outcomes. Its services cater to a diverse clientele, including health providers, private individuals, and businesses, aiming to transform the landscape of mental healthcare through scalable digital products and therapeutics.

Ieso Digital Health Ltd. is a United Kingdom-based company specializing in online evidence-based mental health therapy. Founded in 2000 and formerly known as PsychologyOnline.co.uk Limited, Ieso provides a platform for one-to-one therapy sessions, allowing patients to engage with accredited therapists in a virtual environment tailored to their schedules. The company addresses a variety of mental health conditions, including anxiety, depression, eating disorders, and relationship issues, as well as chronic physical health problems and cognitive impairments. Utilizing cognitive behavioral therapy (CBT), Ieso employs proprietary technology enhanced by natural language processing and artificial intelligence to facilitate real-time monitoring and improve therapeutic outcomes. Its services cater to a diverse clientele, including health providers, private individuals, and businesses, aiming to transform the landscape of mental healthcare through scalable digital products and therapeutics.

Generate Biomedicines, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapeutics through its pioneering platform in Generative Biology. Established in 2018, the company utilizes machine learning to analyze existing proteins, enabling it to understand the principles governing the relationship between genetic sequences and protein structure. This approach facilitates the invention of novel antibodies, peptides, enzymes, receptors, and other protein-based therapeutics optimized for specific biological functions. By harnessing its advanced technology, Generate Biomedicines aims to accelerate drug discovery by generating new biological molecules with significant therapeutic potential. Originally known as Generate Biologics, the company adopted its current name in March 2020 to reflect its expanded focus on biomedicine.

Geneoscopy, LLC is a diagnostics company based in Saint Louis, Missouri, that specializes in non-invasive colorectal cancer screening and gastrointestinal disease management. Founded in 2015, Geneoscopy has developed a platform technology that utilizes stool-derived eukaryotic RNA (seRNA) to create a multi-target RNA biomarker panel. This innovative approach allows for the identification of colorectal cancer by capturing the downstream effects of cancer-causing DNA mutations. The company's diagnostic test aims to improve compliance with colorectal cancer screening, facilitate early-stage detection of neoplasms, and ultimately reduce morbidity and mortality associated with the disease. Additionally, Geneoscopy is exploring other applications of its technology for various gastrointestinal conditions, aiming to provide reliable alternatives to traditional invasive procedures like colonoscopy.

For over a decade, CloudMosa has been a pioneer in providing remote browser solutions for users in both the consumer and enterprise sector. We used this same technology to develop Puffin, a secure browser product lineup with a proven track record of over 150 million downloads to date. Our products are engineered to meet the strictest cybersecurity standards against zero-day threats. We strive to provide unparalleled security, speed, and efficiency for our clients. We aim to continue developing innovative products for both individual consumers and businesses alike with our years of expertise. The company was founded in 2009 and headquartered in Cupertino, California, USA.

Block Renovation is a home renovation platform that aims to simplify the complex process of planning, designing, and executing home improvements. Founded by Koda Wang and Luke Sherwin, the company integrates architect-grade design, construction labor, and materials into a cohesive experience. By bringing design, sourcing, and project management under one roof, Block Renovation provides homeowners with clarity regarding outcomes, quality, pricing, and timelines. This streamlined approach not only enhances the renovation experience for homeowners but also offers contractors a more efficient way to operate. Ultimately, Block Renovation seeks to improve living spaces while elevating the standards of the renovation industry.

DeepCure Inc. is a biotechnology company based in Boston, Massachusetts, specializing in artificial intelligence-driven drug discovery. Founded in 2018, DeepCure develops innovative solutions for small-molecule drug development, utilizing advanced deep learning algorithms and a proprietary database of chemical compounds. The company offers services such as De-novo Lead Discovery, which employs AI algorithms to assess potential drug candidates from a virtual library, and Artificial Intelligence-driven Lead Optimization, aimed at enhancing drug development processes. Additionally, DeepCure's platform includes a molecular database designed to maximize the diversity and synthesizability of chemical compounds. By integrating AI predictive modeling and a feedback loop, DeepCure focuses on creating effective therapeutics for unmet medical needs, ultimately aiming to expedite the development of novel precision medicines.

Robigo is a biomanufacturing company focused on engineering microbes to develop sustainable crop protection solutions. The company creates precision microbial treatments aimed at enhancing plant health and recovering lost agricultural yields. By leveraging microbial engineering and data science, Robigo produces products that are designed to be more effective while ensuring safety for beneficial microbes, pollinators, humans, and the environment. This approach enables farmers to improve their financial performance while promoting sustainable agricultural practices.

Huckleberry makes behavioral expertise accessible and affordable to all families by combining AI with human experts, starting with children's sleep.

EasyExpunctions.com is a legal platform that offers a cost-effective solution for individuals seeking to erase their criminal records without the need for an attorney. The service employs a unique, patent-pending process that sets it apart from other legal software providers. By focusing exclusively on generating legal documents for reputation management, EasyExpunctions allows users to navigate the expunction process efficiently and affordably. This innovative approach empowers individuals to manage their legal records independently, eliminating the high costs associated with traditional legal services.

Kappa Pay is a fintech platform that utilizes blockchain technology to streamline payment processes for both local and cross-border transactions. The company aims to provide an affordable and reliable solution for individuals and merchants, facilitating seamless payments that resemble the simplicity of sending a message. By focusing on removing friction and barriers in financial transactions, Kappa enables users to send and receive money globally with higher transaction limits, enhancing the overall efficiency of the payment experience.

BetterUp Inc. is a leadership development company that offers an innovative online platform aimed at enhancing the personal and professional growth of individuals and organizations. Founded in 2013 and headquartered in San Francisco, BetterUp specializes in virtual coaching, providing users with personalized guidance through one-on-one sessions with a network of over 3,000 coaches available in 46 languages across more than 90 countries. The platform focuses on fostering mental fitness, career and leadership development, and social connection, thereby enabling employees to develop new behaviors and skills that promote high performance in a rapidly changing work environment. With a client base that includes prominent organizations such as NASA, Google, and Hilton, BetterUp has established itself as a leader in the field of mental health and coaching. The company is supported by a distinguished Science Board composed of experts in positive psychology and human performance, further enhancing its credibility and impact in the industry.

Exo Therapeutics, Inc. is a drug discovery and development company focused on addressing challenging pharmaceutical targets. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes its proprietary ExoSight platform to create a pipeline of drug candidates that target exosites, which are unique and distal binding pockets on enzymes. This innovative approach aims to reprogram enzyme activity, leading to precise and effective therapeutic outcomes, particularly in oncology and inflammation, while also minimizing potential side effects for patients. Exo Therapeutics is committed to unlocking breakthrough therapeutics through its team of experienced researchers and a deep understanding of complex disease mechanisms.

Angitia Biopharmaceuticals is a global biotechnology company dedicated to the discovery and development of innovative therapeutics targeting serious musculoskeletal diseases. The company specializes in researching and developing breakthrough therapies for conditions affecting bones, muscles, and joints. By focusing on creating novel drugs, Angitia aims to provide effective treatments that enhance patient recovery from severe musculoskeletal ailments.

HOMEE, Inc. is a technology company based in Tampa, Florida, founded in 2017. It offers a mobile application that connects homeowners, renters, and property managers with skilled service providers such as handymen, plumbers, electricians, and HVAC technicians. The platform facilitates both scheduled and emergency home service transactions, making it easier for users to find and hire the necessary services. Additionally, HOMEE provides tools that enhance the claims process for insurers and policyholders by connecting them with service providers, thereby streamlining emergency mitigations and repairs. Through its integrated platform, HOMEE aims to improve the efficiency of the claims service process and enhance user satisfaction.

SemiosBio Technologies Inc. offers innovative pest management solutions for growers of tree fruits, nuts, and grapes globally. The company has developed the Semios platform, which enables real-time monitoring and control of agricultural operations through a comprehensive network of sensors. This platform provides continuous coverage and includes features such as automated pheromones, pest traps, and pest pressure notifications, along with frost monitoring and alerts. Additionally, it evaluates disease risk, monitors irrigation, and assesses soil conditions, helping growers make informed decisions to optimize crop quality while reducing agricultural inputs. Founded in 2009 and headquartered in Vancouver, Canada, Semios also operates locations in Fresno, California; Wenatchee, Washington; and Heerlen, the Netherlands.

Alamar Biosciences, founded in 2018 and headquartered in Fremont, California, specializes in developing advanced technologies for the early detection and treatment of cancer and other diseases. The company focuses on a precision proteomics platform that facilitates protein analysis and the creation of antibody technologies. This platform is designed to enhance the diagnosis of diseases, particularly cancer, while also supporting the discovery of new biomarkers. By enabling healthcare providers to detect diseases at an early stage, Alamar Biosciences aims to improve patient outcomes through timely interventions and potential cures.

OptoGlo is a product development company specializing in innovative light and color display technologies. It focuses on creating advanced optical solar signs that combine backlit illumination with solar-powered energy, offering enhanced visibility for advertising and event promotions both day and night. The company utilizes nanotechnology to produce transparent illumination and ultra-high-definition displays, positioning itself as a leader in the industry. In addition to product development, OptoGlo licenses intellectual property and collaborates with partners to establish product distribution companies, expanding the reach of its cutting-edge solutions.

MedRhythms Inc. is a neuro-rehabilitation company that specializes in neurologic music therapy, employing sensors, music, and artificial intelligence to create evidence-based interventions aimed at enhancing walking and overall functional outcomes. Founded in 2015 and headquartered in Portland, Maine, the company addresses the needs of individuals affected by neurological conditions such as traumatic brain injury, stroke, Parkinson’s disease, and Huntington’s disease. By merging music with neuroscience and technology, MedRhythms develops programs that focus on sensorimotor, speech, language, and cognitive rehabilitation goals, allowing patients to leverage music as a therapeutic tool to stimulate brain function and improve their quality of life.

Amylyx Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for neurodegenerative diseases, particularly Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s disease, and Wolfram syndrome. Founded in 2013 and based in Cambridge, Massachusetts, the company is best known for its investigational therapy AMX0035, a fixed-dose co-formulation of sodium phenylbutyrate and Taurursodiol. This treatment aims to address the energy crisis within mitochondria and the accumulation of toxic, unfolded proteins in the endoplasmic reticulum, both of which contribute to the progression of neurodegenerative conditions. Through its research and development efforts, Amylyx seeks to provide effective solutions to mitigate the suffering caused by these debilitating diseases.

Block Renovation is a home renovation platform that aims to simplify the complex process of planning, designing, and executing home improvements. Founded by Koda Wang and Luke Sherwin, the company integrates architect-grade design, construction labor, and materials into a cohesive experience. By bringing design, sourcing, and project management under one roof, Block Renovation provides homeowners with clarity regarding outcomes, quality, pricing, and timelines. This streamlined approach not only enhances the renovation experience for homeowners but also offers contractors a more efficient way to operate. Ultimately, Block Renovation seeks to improve living spaces while elevating the standards of the renovation industry.

Fount Bio is a life science company founded in 2018 and headquartered in Cambridge, Massachusetts. The company specializes in developing innovative solutions for skin health, leveraging proprietary advances in glycopolymer research. Fount Bio's products focus on creating a durable hyaluronic acid network within the skin through topical applications. By addressing the delivery and biostability challenges associated with traditional methods, the company aims to unlock the full benefits of hyaluronic acid for consumers, offering alternatives to invasive injection therapies in the beauty and skin health sectors.

Linus Health, Inc. is a digital health company based in Waltham, Massachusetts, founded in 2019. It specializes in developing a brain health monitoring platform that utilizes digital screening technology to enhance the assessment and treatment of cognitive and mental health. The platform collects various digital measurements, including voice, speech, gait, cognition, and eye movement, aimed at early detection and diagnosis of brain health issues. Additionally, Linus Health provides clinical decision support and care planning tools, enabling healthcare providers to offer actionable recommendations based on the insights gathered. The company's mission focuses on transforming brain health, making it accessible to individuals worldwide.

Triastek Co. Ltd., established in 2015 and headquartered in Nanjing, China, specializes in the manufacturing of 3D printed pharmaceuticals and related medical equipment. The company offers a range of drugs, including blockbuster and orphan drugs, along with complex drug delivery technologies. Triastek's portfolio includes 3D drug printing services, such as formulation design, equipment, and development methods, with patents secured in key global markets like China, the US, Europe, and Japan. Notably, the company owns Melt Extrusion Deposition (MED), a universally applicable 3D printing technology for solid formulations. Triastek's mission is to revolutionize drug delivery, development, and manufacturing through its proprietary 3D printing technology.

Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, specializing in the development of innovative therapies for advanced liver diseases and cancers associated with Claudin-1 (CLDN1) expression. Founded in 2019, Alentis focuses on addressing conditions such as liver fibrosis, cirrhosis, and liver cancer through the use of anti-CLDN1 antibody-drug conjugates and other targeted treatments. The company's unique approach combines clinically relevant read-outs with advanced techniques like single-cell RNA sequencing of patient liver tissues, aiming to reverse disease progression and improve patient outcomes. Alentis Therapeutics is recognized for its pioneering role in exploring anti-CLDN1 therapeutics, contributing to advancements in the treatment of fibrotic diseases and CLDN1-positive tumors.

Stealth BioTherapeutics is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of innovative therapies targeting diseases associated with mitochondrial dysfunction. Founded in 2006 and headquartered in George Town, the Cayman Islands, the company’s lead product candidate, Elamipretide, aims to address both rare genetic and common age-related mitochondrial diseases. Additionally, Stealth BioTherapeutics is developing SBT-20, a small peptide designed to stabilize mitochondrial structure and function under oxidative stress, and SBT-272, which is being evaluated for its potential in treating rare neurodegenerative disorders, including amyotrophic lateral sclerosis. By focusing on mitochondrial health, Stealth BioTherapeutics seeks to improve outcomes for patients suffering from these challenging conditions.

Coin Metrics Inc. is a provider of blockchain and cryptocurrency data analytics, based in Cambridge, Massachusetts. Founded in 2017, the company specializes in delivering market and network data, analytics, and research to various industries and institutions involved in crypto-assets. Its offerings include the CM Network Data Pro, which provides comprehensive historical data on top cryptocurrency assets, and the CM Market Data Feed, which standardizes trade, candle, and order book data from multiple exchanges. Additionally, Coin Metrics offers CM Reference Rates, which present fixed asset pricing in U.S. dollars. By focusing on transparency and actionable data, Coin Metrics aims to empower individuals and organizations to make informed financial decisions related to cryptocurrencies.

Nebula Microsystems delivers intelligent and high-performance Analog Products for a wide variety of applications including communication, consumer, industrial, healthcare, and automotive. Power converters, high-speed SERDES, high-performance amplifiers, data converters, and high-power density DC-DC and AC-DC products are among the products offered by Nebula Microsystems.

Catalant is a Boston-based software company that specializes in strategy execution solutions for global enterprises. Founded in 2013, the company's platform enables businesses to break down strategic objectives, access and deploy resources, collaborate, measure value, and improve processes. Catalant's network comprises over 65,000 experts and 1,000 firms, serving more than 30% of the Fortune 100. Additionally, Catalant offers a platform that connects private equity firms with business professionals.

Endolytix is a biotechnology company focused on developing innovative therapeutic solutions to combat antibiotic resistance, particularly in non-tuberculous mycobacterial (NTM) infections. The company's therapies are designed to effectively kill pathogenic bacteria, including those that are multidrug-resistant, thereby enabling healthcare providers to manage infections that are notoriously difficult to treat. Through its novel approaches, Endolytix aims to enhance the efficacy of treatments available for the most resistant antibiotic infections, addressing a critical need within the healthcare industry.

Apnimed, Inc. is a clinical-stage company based in Cambridge, Massachusetts, focused on developing innovative pharmacologic therapies for sleep apnea and related disorders. Founded in 2017, Apnimed aims to address the underlying neurobiological mechanisms that contribute to obstructive sleep apnea (OSA), a serious condition affecting over 20 million Americans. Current treatment options primarily involve positive pressure devices, which can be cumbersome, while Apnimed's approach seeks to provide a simpler, safe, and effective orally dosed medication. The company's therapeutics target both the physiological and symptomatic effects of OSA, with the goal of improving daily functioning and reducing the significant morbidity and mortality associated with this disorder.

Stavvy, Inc. is a financial technology company based in Boston, Massachusetts, that specializes in a digital mortgage vendor platform aimed at transforming the lending experience. Founded in 2018 and originally named Stavros Technologies, the company provides tools such as Stavvy Connect, which facilitates secure communication and access to vendor data for mortgage banking professionals during the underwriting and settlement processes. Additionally, Stavvy Notarize enables title agents, lawyers, and notaries to conduct virtual closings and meetings in real-time using web conference technology. By eliminating paper-based processes and enhancing communication, Stavvy aims to improve operational efficiency while minimizing risk for its users in the mortgage industry.

PhoreMost Limited is a drug discovery company based in Cambridge, United Kingdom, established in 2014. The company specializes in identifying new druggable targets for cancer and other unmet medical needs through its innovative Site-Seeker platform. This platform systematically reveals cryptic druggable sites within the human genome and connects them to therapeutic functions in a live-cell context. By utilizing functionally validated protein fragments, PhoreMost informs the design of small molecule drugs that can be developed into targeted therapies. The company collaborates with a global network of academic and industrial partners to efficiently advance novel therapies to market, aiming to reduce costs and improve accessibility for patients.

Arctic Vision is a clinical-stage specialty ophthalmology company based in China, focused on developing innovative therapies to meet the unmet clinical needs in ophthalmic diseases. The company boasts a leading portfolio of breakthrough technologies aimed at addressing various eye care challenges in China, Asia, and globally. Established by prominent life sciences investors, Arctic Vision is guided by a team of experienced professionals from the ophthalmic industry, who possess extensive knowledge in research and development as well as commercialization of eye care products. The company's efforts include the development of new ophthalmic medicines, particularly gene therapies, that hold significant commercial potential and aim to improve the recovery outcomes for patients with rare ophthalmic conditions.

Monument Bank, established in 2017 and located in London, United Kingdom, is a commercial bank that serves mass affluent clients, including professionals, property investors, and entrepreneurs. The bank specializes in providing savings accounts and a variety of property loans, including buy-to-let loans and bridging loans. Monument is focused on delivering tailored financial services to meet the needs of its members, positioning itself as a trusted partner for individuals seeking to manage their wealth and investment opportunities effectively.

Zhishan Weixin Biotechnology integrates gene-drug research and development to treat genetic and neurodegenerative diseases. The company focuses on the research and development and subversive production of rAAV gene drugs. Zhishan Weixin's therapeutic areas cover blood diseases, rare diseases, and other disease areas.

Rockley Photonics Limited, founded in 2013 and based in London, United Kingdom, specializes in developing silicon photonics technologies for diverse applications. The company focuses on creating integrated optical modules, sensors, and comprehensive solutions that cater to high-volume and dynamic market sectors. Rockley aims to revolutionize mobile health monitoring and machine vision with its next-generation sensing platforms, while also providing high-speed solutions for data communications. By leveraging its innovative photonic integrated circuits and associated modules, Rockley is positioned to address a wide array of vertical applications, believing that photonics will become as ubiquitous as microelectronics in the future. The company combines hardware with supporting electronics, software, application algorithms, and AI platforms, establishing a robust foundation for future developments across multiple industries.

Innodem Neurosciences is a Canadian company founded in 2016 that specializes in developing artificial intelligence-driven mobile software designed to enhance communication for paralyzed and intubated patients through eye movements. The company’s flagship product, Pigio, utilizes advanced eye-tracking technology to facilitate interaction between patients and caregivers. Additionally, Innodem's technology serves as a digital biomarker tool that aids in the diagnosis and monitoring of neurodegenerative diseases. By enabling self-testing and tracking disease progression, the technology allows clinicians to assess treatment effectiveness and make informed adjustments to patient care. Overall, Innodem Neurosciences is dedicated to improving the quality of life for patients and establishing a patient-centric approach in healthcare.

NewAmsterdam Pharma, established in 2019 and headquartered in Naarden, the Netherlands, is a late-stage biopharmaceutical company dedicated to improving patient care in cardio-metabolic disease populations. The company's primary focus is the development of transformative therapies, with its lead product, obicetrapib, being a next-generation, oral, low-dose CETP inhibitor designed to lower LDL-C levels more effectively than current treatments, particularly for patients with statin intolerance or Arteriosclerotic Cardiovascular Disease/Familial Hypercholesterolemia (ASCVD/FH) on maximally-tolerated statin therapy.

30 Technology is a biopharmaceutical platform developer focused on improving the lives of patients facing serious and life-threatening medical conditions. The company specializes in harnessing the therapeutic potential of nitric oxide to create innovative treatments that enhance patient healing and bolster defense mechanisms. By facilitating the development of new models of care, 30 Technology aims to provide healthcare professionals with effective tools to address a range of critical medical issues, ultimately striving to advance patient outcomes and quality of life.

Curai Health is a virtual care company founded in 2017 by Neal Khosla and Xavier Amatriain, headquartered in Palo Alto. The company specializes in providing affordable primary care through a chat-based interface that integrates artificial intelligence with human clinicians. This approach leverages advanced machine learning tools to streamline patient interactions and enhance diagnostic accuracy. By creating a responsive learning healthcare system, Curai Health aims to make high-quality primary care accessible to everyone, reducing the overall cost of care delivery. The service is available directly to consumers and can also be accessed through enterprise partnerships, emphasizing its commitment to improving healthcare accessibility and affordability.

Beijing Dip Technology Co., Ltd., also known as DEEPEXI, is a leading enterprise in digital transformation, focusing on providing comprehensive consulting, solutions, products, and technology research and development. Established in May 2018, the company is headquartered in Beijing and operates branches in major cities such as Guangzhou, Shenzhen, Nanjing, and Chengdu. With a workforce of 160 employees, over 80% of whom are dedicated to research and development, DEEPEXI boasts a highly skilled team that includes experts in artificial intelligence and open-source technologies. The company specializes in delivering scalable business intelligence services that leverage a cloud-native Internet framework, integrating cutting-edge technologies such as 5G, IoT, big data, and cloud computing. This enables enterprises to utilize data intelligence effectively in their decision-making processes and business strategies.

Tallac Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative immunotherapies for cancer patients. Founded in 2018 and headquartered in Burlingame, California, the company specializes in creating conjugates of antibodies combined with potent toll-like receptor agonists. This approach aims to activate both innate and adaptive immunity, enabling targeted immune responses against various solid tumor malignancies. Through its advanced therapies, Tallac Therapeutics seeks to enhance the immune system's ability to combat cancer more effectively.

Neuroelectrics is a digital brain health company founded in 2012 and based in Barcelona, Catalonia. It specializes in non-invasive electrical brain stimulation technology, focusing on personalized neuromodulation. The company has developed advanced wireless EEG and stimulation devices, including tDCS, tACS, and tRNS, with capabilities of up to 32 channels. These products, along with accompanying software and research services, are designed to monitor and enhance brain health by measuring and modifying brain function. Neuroelectrics aims to assist medical professionals in restoring brain health, reducing disabilities, and improving the quality of life for patients.

CellCentric Ltd. is a biotechnology company based in Cambridge, United Kingdom, focused on developing innovative cancer therapeutics. Established in 2003, the company specializes in small-molecule inhibitors targeting p300, CBP, and specific deubiquitinase enzymes, which play a crucial role in regulating gene expression in cancer cells. Its primary research program addresses prostate cancer, a significant cause of male mortality, by modulating the androgen receptor pathway and potentially overcoming resistance mechanisms found in existing treatments. Additionally, CellCentric's products have applications in treating other cancers, including non-small cell lung cancer, breast cancer, and colon cancer. The company's approach aims to provide targeted therapies for various malignancies, addressing unmet medical needs in the oncology field.

InCarda Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cardiovascular diseases. Founded in 2009 and based in Newark, California, the company specializes in a novel inhaled treatment approach to manage acute cardiovascular conditions. Its lead product, InRhythm, is an inhaled formulation of an antiarrhythmic drug designed to treat paroxysmal atrial fibrillation quickly, allowing patients to administer the therapy in various settings, such as at home or work. By delivering medication directly to cardiac tissue, InCarda's therapy aims to provide effective treatment for atrial arrhythmias with a simplified approach. The company has completed Phase 1 clinical trials and is currently advancing its lead product through Phase 2 trials.

Revolo Biotherapeutics is a company focused on developing innovative therapies for autoimmune and allergic diseases. Founded in 2011, originally known as Immune Regulation, the company aims to achieve superior long-term disease remission through less frequent chronic dosing without suppressing the immune system. Its anti-inflammatory peptides are designed to treat immuno-inflammatory diseases such as asthma, atopic dermatitis, and inflammatory bowel diseases, offering patients improved treatment options and quicker recovery.

LeLe Ketang is an online education platform based in Beijing, China, specializing in K-12 education services. Founded in 2014, the company primarily focuses on providing online training courses for primary and secondary school students, emphasizing subjects such as math and language. LeLe Ketang utilizes innovative teaching methods, including three-minute video lectures and gamification elements, to engage students effectively. Additionally, the platform offers personalized learning experiences through one-on-one interactions, enhancing the educational journey for its users.

Prescryptive Health, Inc. is a digital health company that operates a prescription benefits platform aimed at enhancing the accessibility and affordability of medications for both payers and patients. Established in 2017 and based in Redmond, Washington, the company provides services that include analyzing current plan designs, recommending new plans, and facilitating member enrollment. Its platform empowers users by offering direct access to market pricing, unbiased information, and real-time cost insights regarding prescribed treatments. This includes details on insurance coverage, out-of-pocket expenses, and available lower-cost alternatives. Prescryptive Health serves a diverse range of clients, including employers, health plans, providers, pharmacies, and pharmaceutical companies, with the goal of democratizing the prescription drug market.

F2G Ltd is a biotechnology company focused on developing innovative therapies for serious fungal infections. Founded in 1998 and based in Manchester, United Kingdom, F2G primarily works on its F3 series of anti-mold compounds, specifically targeting antifungal agents against Aspergillus and other filamentous molds. Utilizing proprietary genomics technology known as MycoBank, the company identifies essential gene targets in fungi, which informs its drug development process. F2G has diversified its approach to include chemistry-driven discovery, leveraging a strong development team to advance its patented compounds. The company's efforts aim to address difficult-to-treat fungal pathogens that pose significant mortality risks, particularly for immunocompromised patients, thereby enhancing treatment options in the pharmaceutical industry.

Vesigen Therapeutics, established in 2020 and based in Cambridge, Massachusetts, specializes in developing innovative therapeutic products. The company's core technology, ARMMs (ARRDC1 Mediated Microvesicles), facilitates the delivery of various payloads such as RNAs, proteins, and gene-editing complexes directly into the cytoplasm of target cells. This approach overcomes intracellular delivery barriers, expanding the scope of treatable conditions and enabling new therapies for unmet medical needs.

Arctic Vision is a clinical-stage specialty ophthalmology company based in China, focused on developing innovative therapies to meet the unmet clinical needs in ophthalmic diseases. The company boasts a leading portfolio of breakthrough technologies aimed at addressing various eye care challenges in China, Asia, and globally. Established by prominent life sciences investors, Arctic Vision is guided by a team of experienced professionals from the ophthalmic industry, who possess extensive knowledge in research and development as well as commercialization of eye care products. The company's efforts include the development of new ophthalmic medicines, particularly gene therapies, that hold significant commercial potential and aim to improve the recovery outcomes for patients with rare ophthalmic conditions.

neoX Biotech is a Beijing-based biotechnology company founded in 2018 that specializes in the development of antigen-based cancer vaccines. By integrating artificial intelligence with biophysics, neoX Biotech focuses on the discovery and development of macromolecular and multispecific drugs, primarily in the field of immuno-oncology. The company has established a platform for early therapeutic discovery, which includes neoantigen prediction and T cell receptor screening, as well as the characterization of protein-protein interactions. This innovative approach aims to provide effective treatments for cancer patients by advancing drug research and development.

Amylyx Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for neurodegenerative diseases, particularly Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s disease, and Wolfram syndrome. Founded in 2013 and based in Cambridge, Massachusetts, the company is best known for its investigational therapy AMX0035, a fixed-dose co-formulation of sodium phenylbutyrate and Taurursodiol. This treatment aims to address the energy crisis within mitochondria and the accumulation of toxic, unfolded proteins in the endoplasmic reticulum, both of which contribute to the progression of neurodegenerative conditions. Through its research and development efforts, Amylyx seeks to provide effective solutions to mitigate the suffering caused by these debilitating diseases.

Big Health is a digital therapeutics company headquartered in London, United Kingdom, that specializes in developing and marketing innovative behavioral health programs. The company's flagship product, Sleepio, is a digital sleep improvement program that employs Cognitive Behavioral Therapy techniques to address and personalize sleep disorders. By offering a fully automated healthcare portal, Big Health delivers highly personalized digital therapeutics and behavioral programs aimed at tackling various mental health issues. Their approach combines medical consultation with user-friendly technology, enabling individuals to effectively manage and overcome sleep-related disorders in an efficient manner.

Prilenia is a clinical-stage biotechnology company focused on developing innovative treatments for neurodegenerative and neurodevelopmental disorders. Founded in 2018 and operating from locations in Israel, the Netherlands, and Boston, the company’s primary asset is Pridopidine, an oral drug candidate noted for its established safety profile. Pridopidine demonstrates potential in treating various movement disorders and neurodegenerative diseases that affect both adults and children, aiming to help healthcare institutions preserve functional capacity in patients, including those undergoing early hemodialysis.

Heyuan Biotechnology is a biotechnology company focusing on the field of gene therapy services. They offer gene therapy vectors, gene function research, drug targets, and efficacy for the basic research of gene therapy research, among other services.